Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Dosing regiment in the combination of ipilimumab and nivolumab in stage III melanoma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 29.10.18
Views: 613

Dr Lisette Rozeman - Netherlands Cancer Institute, Amsterdam, Netherlands

Dr Lisette Rozeman speaks with ecancer at ESMO 2018 in Munich about the study into a more tolerable dosing regiment of the combination of ipilimumab and nivolumab with the same efficacy in stage III melanoma.

Dr Rozeman explains that lowering the dose of the ipilimumab and running only two cycles reduced the number of patients receiving adverse events.

She states that the response rate was still preserved, with only a small difference between the first two arms.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

CML Life Banner

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation